Name:
Genomic evolution shapes....pdf
Size:
13.97Mb
Format:
PDF
Description:
Found with Open Access Button
Authors
Woodcock, D. J.Sahli, A.
Teslo, R.
Bhandari, V.
Gruber, A. J.
Ziubroniewicz, A.
Gundem, G.
Xu, Y.
Butler, A.
Anokian, E.
Pope, B. J.
Jung, C. H.
Tarabichi, M.
Dentro, S. C.
Farmery, J. H. R.
Van Loo, P.
Warren, A. Y.
Gnanapragasam, V.
Hamdy, F. C.
Bova, G. S.
Foster, C. S.
Neal, D. E.
Lu, Y. J.
Kote-Jarai, Z.
Fraser, M.
Bristow, Robert G
Boutros, P. C.
Costello, A. J.
Corcoran, N. M.
Hovens, C. M.
Massie, C. E.
Lynch, A. G.
Brewer, D. S.
Eeles, R. A.
Cooper, C. S.
Wedge, David C
Affiliation
Division of Cancer Sciences, Health and Medicine, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; CRUK Manchester Institute, University of Manchester, Manchester, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression.Citation
Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, et al. Genomic evolution shapes prostate cancer disease type. Cell genomics. 2024 Mar 13;4(3):100511. PubMed PMID: 38428419. Pubmed Central PMCID: PMC10943594. Epub 2024/03/02. eng.Journal
Cell GenomicsDOI
10.1016/j.xgen.2024.100511PubMed ID
38428419Additional Links
https://dx.doi.org/10.1016/j.xgen.2024.100511Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.xgen.2024.100511
Scopus Count
Collections
Related articles
- Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells.
- Authors: Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P
- Issue date: 2014
- Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
- Authors: Hess-Wilson JK, Webb SL, Daly HK, Leung YK, Boldison J, Comstock CE, Sartor MA, Ho SM, Knudsen KE
- Issue date: 2007 Nov
- Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
- Authors: Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J
- Issue date: 2018 Dec 10
- Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.
- Authors: Brand LJ, Dehm SM
- Issue date: 2013 Apr
- An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
- Authors: Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, Korn WM, Heath EI
- Issue date: 2020 Jun